About Careers Internship MedBlog Contact us
Medindia LOGIN REGISTER
Dapagliflozin Could be Used as Supportive Drug For Type 1 Diabetes
Advertisement

Dapagliflozin Could be Used as Supportive Drug For Type 1 Diabetes

Font : A-A+

Highlights
  • Type 1 diabetics who were treated with dapagliflozin observed a decline in blood sugar levels.
  • There was no finding of ketoacidosis, a dangerous complication that occurs when acids and substances called ketones build up in the blood due to lack of insulin.
  • Dapagliflozin is usually prescribed for type 2 diabetics.

Patients with Type 1 diabetes who were treated with dapagliflozin had a significant decline in their blood sugar levels. Dapagliflozin, a medicine prescribed for Type 2 diabetes and was tested for type 1 diabetics.

The drug is a sodium glucose cotransporter-2 inhibitor (SGLT-2) which was given as an adjunct therapy in addition to the insulin that patients with Type 1 diabetes need to survive.

Advertisement

Dapagliflozin Could be Used as Supportive Drug For Type 1 Diabetes

In 2011, Dandona published an observational study that found that another drug for Type 2 diabetes, liraglutide, could help treat Type 1 diabetes but there was a risk of increase in ketone levels in the blood.

"Our paper provides the initial signal that dapagliflozin is safe and effective in patients with Type 1 diabetes and is a promising adjunct treatment to insulin to improve glycemic control," said senior author Dr.Paresh Dandona, University at Buffalo.
Advertisement

Dapagliflozin For Type 1 Diabetics

The study, called, Dapagliflozin in Patients with Inadequately Controlled Type 1 diabetes (DEPICT-1) is the first global multicenter investigation of dapagliflozin to test its efficacy and safety in Type 1 diabetes.

It was a multicenter study conducted at 143 sites in 17 countries. The double-blind, randomized, three-arm, phase 3 was funded by AstraZeneca and Bristol-Myers Squibb, the companies that partnered to develop dapagliflozin.

For the study, 833 patients aged 18-75 who had inadequately controlled blood sugars with a mean baseline hemoglobin A1C (HbA1c) of 8.53 were recruited. HbA1c is a measure of sugar in the blood. For Type 1 diabetics, HbA1clevels under 7 is considered normal.

Dr.Paresh Dandona said, "The 24-week results from DEPICT-1 are important as they represent the first Phase 3 trial in Type 1 diabetes of the newer, selective SGLT-2 class of diabetes medicines as an oral adjunct to insulin," he said.

Study Findings

Approximately half of the patients taking dapagliflozin reduced their A1C levels by more than 0.5 percent without experiencing severe hypoglycemia. Dandona explained that any fall in HbA1c of around 0.5 percent is considered significant and can lead to licensing of a drug as an antidiabetic agent. However, that the findings will need further confirmation before the drug can be licensed by the FDA for use in Type 1 diabetes.

There was no finding of ketoacidosis, a dangerous complication that occurs when acids and substances called ketones build up in the blood due to lack of insulin.

"We found out that any reduction of insulin dose greater than 20 percent, or the absence of a meal and missing the insulin dose, or the significant intake of alcohol makes you more vulnerable to ketoacidosis," he explained.

"Treating the millions of patients living with Type 1 diabetes while also managing the complications associated with the disease remains a daunting challenge," said Dandona. The final results of the study will be released after 56 weeks. "If the outcomes are sustained or better at that time, and if a parallel study, DEPICT-2, confirms this, there will likely be an application to the FDA for licensing the drug for use in Type 1 diabetes," he said.

Reference
  1. Paresh Dandona et al., Drug for type 2 diabetes provides significant benefits to type 1 diabetic patients, Lancet Diabetes and Endocrinology (2017).


Source: Medindia

Citations   close

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Julia Samuel. (2017, September 18). Dapagliflozin Could be Used as Supportive Drug For Type 1 Diabetes. Medindia. Retrieved on Aug 19, 2022 from https://www.medindia.net/news/healthwatch/dapagliflozin-could-be-used-as-supportive-drug-for-type-1-diabetes-173087-1.htm.

  • MLA

    Julia Samuel. "Dapagliflozin Could be Used as Supportive Drug For Type 1 Diabetes". Medindia. Aug 19, 2022. <https://www.medindia.net/news/healthwatch/dapagliflozin-could-be-used-as-supportive-drug-for-type-1-diabetes-173087-1.htm>.

  • Chicago

    Julia Samuel. "Dapagliflozin Could be Used as Supportive Drug For Type 1 Diabetes". Medindia. https://www.medindia.net/news/healthwatch/dapagliflozin-could-be-used-as-supportive-drug-for-type-1-diabetes-173087-1.htm. (accessed Aug 19, 2022).

  • Harvard

    Julia Samuel. 2021. Dapagliflozin Could be Used as Supportive Drug For Type 1 Diabetes. Medindia, viewed Aug 19, 2022, https://www.medindia.net/news/healthwatch/dapagliflozin-could-be-used-as-supportive-drug-for-type-1-diabetes-173087-1.htm.

Advertisement

Advertisement
News A-Z
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
What's New on Medindia
Test Your Knowledge on Liver Transplantation
Organ Donation Week 2022 - 'Take the Pledge to Save Lives'
Test your Knowledge on Heart Transplantation
View all
Recommended Reading
News Archive
Date
Category
Advertisement
News Category

Medindia Newsletters Subscribe to our Free Newsletters!
Terms & Conditions and Privacy Policy.

More News on:
Diabetic Retinopathy Drug Toxicity Diabetes Diabetic Diet Otitis Media Diabetes - Essentials Diabetes - Self-Monitoring of Blood Glucose (SMBG) Insulin Delivery Devices Diabetes and Exercise Signature Drug Toxicity 

Most Popular on Medindia

Vent Forte (Theophylline) Indian Medical Journals How to Reduce School Bag Weight - Simple Tips Diaphragmatic Hernia Iron Intake Calculator Color Blindness Calculator Drug Interaction Checker Drug - Food Interactions Find a Hospital Nutam (400mg) (Piracetam)
This site uses cookies to deliver our services. By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use